Orthoplastics is pleased to announce plans for the opening of an additional manufacturing facility in the UK.
A world leader in the development and supply of implantable-grade plastics used within the Orthopaedic sector, this expansion is expected to create around 100 new jobs within the local community in years to come.
Official opening expected in 2020
The new building, set to open in February 2020, will enable Orthoplastics to further increase its market capabilities with over £5 million of investment annually. This is a significant move for the business in a rapidly advancing and innovative market and one that is fully supported by US parent company, Viant Inc.
The location of the new facility will be at the Futures Business Park Development in Rossendale (UK). It will fast become a centre of excellence for the business and a launch pad for its extensive global growth plans, designed to ensure Orthoplastics becomes world-leader in polymeric solutions.
Mark Allen, Managing Director, Orthoplastics said: “This significant investment underlines our belief that there is huge potential for innovation and growth within the Orthopaedic sector. It is also the next step towards achieving our ambition of pioneering improved patient outcomes and the longevity of implantable medical devices. Joint replacement procedures such as HIP and knee surgeries are highly successful of course, but we are leading the way in the evolution of new concepts to improve these life changing operations.”
Part of a global, growth strategy
The long-term UK manufacturing investment being made by Orthoplastics demonstrates its confident business strategy. “If the Orthopaedic sector is to grow and thrive, we must embrace new technologies and materials. Our vision and ambition for superior materials solutions perfectly represents how we are putting this strategy into practice with Viant globally.” said Mark Allen.
Providing customers with greater surety
“Innovation is at the heart of the future of UK manufacturing, and this factory will provide our customers with the confidence in our long-term investments strategy, whilst demonstrating our strategic partnership and commitment.” said Mark Allen.
A clear focus on end-to-end solutions
Alton Shader, CEO at Viant commented: “We focus on providing end-to-end solutions for medical device OEMs. Our extensive materials expertise including metals, combined with our experience in engineering, manufacturing, assembly, packaging and sterilization, allows us to bring our customers' medical technology solutions to market.”